CliffBio
small molecule

OCTREOTIDE ACETATE

OCTREOTIDE ACETATE

Loss of exclusivityJuly 2026FDA regulatory exclusivity expiry
CompanyMylan →See this company's full patent-cliff portfolio

Drug detail

Brand nameOCTREOTIDE ACETATE
Active ingredientOCTREOTIDE ACETATE
StrengthEQ 30MG BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalDecember 2025
Marketing statusRX

Regulatory exclusivity

CodeExpires
CGTJuly 2026

More from Mylan

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

OCTREOTIDE ACETATE patent cliff — loss of exclusivity July 2026 | CliffBio